Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Immunomedics Inc - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Immunomedics Inc - Product Pipeline Review - 2016', provides an overview of the Immunomedics Inc's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Immunomedics Inc - The report provides overview of Immunomedics Inc including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Immunomedics Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Immunomedics Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Immunomedics Inc's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Immunomedics Inc - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Immunomedics Inc's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Immunomedics Inc Snapshot 7 Immunomedics Inc Overview 7 Key Facts 7 Immunomedics Inc - Research and Development Overview 8 Key Therapeutic Areas 8 Immunomedics Inc - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Partnered Products 15 Partnered Products/Combination Treatment Modalities 16 Immunomedics Inc - Pipeline Products Glance 17 Immunomedics Inc - Late Stage Pipeline Products 17 Phase III Products/Combination Treatment Modalities 17 Immunomedics Inc - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Immunomedics Inc - Early Stage Pipeline Products 20 Preclinical Products/Combination Treatment Modalities 20 Discovery Products/Combination Treatment Modalities 21 Immunomedics Inc - Unknown Stage Pipeline Products 22 Unknown Products/Combination Treatment Modalities 22 Immunomedics Inc - Drug Profiles 23 14-3s - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 15-3s - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 19-3s - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 1R-15-15 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 1R-2b - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 1R-3s - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 1R-E1-E1 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 20-3s - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 202-b - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 C2-3s - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 E1-3s - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 epratuzumab - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Hex-hR1 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 IMMU-110 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 IMMU-114 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 IMMU-140 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 labetuzumab govitecan - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 M1-3s - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 milatuzumab - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Monoclonal Antibody Conjugate to Target CD19 for B-Cell Hematologic Malignancies - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Monoclonal Antibody Conjugate to Target CEACAM6 for Colon Cancer and Breast Cancer - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Monocloncal Antibody to Target CD-19 for Oncology - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 sacituzumab - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 TF-12 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 TF-2 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 veltuzumab - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 yttrium Y 90 epratuzumab tetraxetan - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Immunomedics Inc - Pipeline Analysis 75 Immunomedics Inc - Pipeline Products by Target 75 Immunomedics Inc - Pipeline Products by Route of Administration 77 Immunomedics Inc - Pipeline Products by Molecule Type 78 Immunomedics Inc - Pipeline Products by Mechanism of Action 79 Immunomedics Inc - Dormant Projects 82 Immunomedics Inc - Discontinued Pipeline Products 83 Discontinued Pipeline Product Profiles 83 clivatuzumab tetraxetan 83 epratuzumab 83 ImmuRAIT-LL2 83 veltuzumab 83 Immunomedics Inc - Company Statement 85 Immunomedics Inc - Locations And Subsidiaries 87 Head Office 87 Other Locations & Subsidiaries 87 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 88 Disclaimer 89
List of Tables
Immunomedics Inc, Key Facts 7 Immunomedics Inc - Pipeline by Indication, 2016 9 Immunomedics Inc - Pipeline by Stage of Development, 2016 13 Immunomedics Inc - Monotherapy Products in Pipeline, 2016 14 Immunomedics Inc - Partnered Products in Pipeline, 2016 15 Immunomedics Inc - Partnered Products/ Combination Treatment Modalities, 2016 16 Immunomedics Inc - Phase III, 2016 17 Immunomedics Inc - Phase II, 2016 18 Immunomedics Inc - Phase I, 2016 19 Immunomedics Inc - Preclinical, 2016 20 Immunomedics Inc - Discovery, 2016 21 Immunomedics Inc - Unknown, 2016 22 Immunomedics Inc - Pipeline by Target, 2016 76 Immunomedics Inc - Pipeline by Route of Administration, 2016 77 Immunomedics Inc - Pipeline by Molecule Type, 2016 78 Immunomedics Inc - Pipeline Products by Mechanism of Action, 2016 80 Immunomedics Inc - Dormant Developmental Projects,2016 82 Immunomedics Inc - Discontinued Pipeline Products, 2016 83 Immunomedics Inc, Other Locations 87 Immunomedics Inc, Subsidiaries 87
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
